Data / Form D filings / Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc.: Form D filings
Unicycive Therapeutics, Inc., a biotechnology company in Los Altos, CA, filed 5 Form D notices with the SEC between 2019 and 2024. The latest, on March 20, 2024, reports $50 million sold of a $50 million offering to 25 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 4300 EL CAMINO REAL, SUITE 210, Los Altos, CA, 94022
- Phone
- (650) 351-4495
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- Decline to Disclose
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1766140
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Mar 20, 2024 | New notice | $50,000,000 | $50,000,000 | 25 | Mar 13, 2024 | sec.gov | |
| Mar 13, 2023 | New notice | $30,190,000 | $30,190,000 | 20 | Mar 3, 2023 | sec.gov | |
| Jun 3, 2020 | New notice | $604,140 | $604,140 | 15 | Oct 1, 2019 | sec.gov | |
| Aug 16, 2019 | New notice | $526,950 | $526,950 | 9 | Mar 12, 2019 | sec.gov | |
| Mar 4, 2019 | New notice | $420,000 | $420,000 | 8 | Feb 21, 2019 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| John Ryan | Director | |
| Gaurav Aggarwal | Director | |
| Sara Kenkare-Mitra | Director | |
| Sandeep Laumas | Director | |
| John Townsend | Executive Officer | |
| Shalabh Gupta | Executive Officer, Director |
Other biotechnology companies in California that filed recently
- Trellis Bioscience, Inc. $9.1 million · Oct 29, 2026
- BigHat Biosciences, Inc. $75.1 million · Oct 26, 2026
- Theravie Pharma, Inc. $750,000 · Oct 19, 2026
- Adela, Inc. $12 million · Oct 19, 2026
- Estuary Biotherapeutics, Inc. $40.7 million · Oct 16, 2026
- Renue Life Sciences, Inc. $250,000 · Oct 14, 2026
Every Form D from the week of Mar 18, 2024 · All recent filings in California · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Unicycive Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.